alliance/partnership

HEALTHPOINT® In Exclusive, Worldwide Agreement to Market COOK® Biotech’s Oasis® Wound Matrix Product

Concerns: alliance/partnership
Released on: 27-Sep-2002

Pharmaceutical form and dosage: Biomaterial

Type:

- Curative
- FP (finished products)
- Pharmaceuticals / Therapeutics
- Prescription drugs (Rx)
- Preventive
- Technology

Therapeutic target:

- Aging
- Dermatology
- Diabetes
- Geriatrics
- Infectious Diseases
- Pain
- Surgery
- Transplant

Concerns the following market:
- United States of America

Other: Worldwide

Full Description:
(Fort Worth, TX, USA) — HEALTHPOINT, Ltd., a Texas-based market leader in tissue management, dermatology, and infection prevention products, has announced that it has signed an exclusive, worldwide agreement with COOK Biotech Incorporated to market its patented, wound matrix product, Oasis.

Based on COOK’s breakthrough Small Intestinal Submucosa, or SIS Technology, Oasis is a natural, extracellular matrix used to manage a variety of wounds by providing an environment that allows the body to heal itself. The term of the agreement is 20 years, and HEALTHPOINT will have the option to extend the term.

Under the agreement, HEALTHPOINT will initially market Oasis in the U.S., Canada, and soon in Mexico and Puerto Rico. Indiana-based COOK Biotech will continue to manufacture the product.

Oasis can be used in the management of partial and full-thickness skin loss injuries, such as pressure, venous and chronic vascular ulcers, diabetic ulcers, surgical and trauma wounds, second degree burns, abrasions, and autograft donor sites.

The SIS Technology, on which Oasis is based, is a new biomaterial that provides a supportive environment to allow a patient’s body to rebuild and repair damaged tissue.

Since its inception in 1992, HEALTHPOINT has established a national presence in the research, development, and marketing of branded pharmaceuticals, over the counter drugs, and medical devices for tissue management, dermatology, and infection prevention. .
HEALTHPOINT, a DFB Pharmaceuticals, Inc. affiliate company, has headquarters in Fort Worth, Texas, USA, with an additional office in Canada.

COOK Biotech Incorporated, located in West Lafayette, Indiana, USA, was established in 1995 to research, develop and manufacture products based on extracellular matrix (ECM) Technology. Medical products utilizing COOK’s patented ECM Technology are currently marketed worldwide for use in wound management and surgical repair of soft tissue.

###

  Contact for this news release: Jay Nisbet